Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
| Autor: | Gligorov, Joseph a, ∗, Pivot, Xavier b, Ataseven, Beyhan c, d, De Laurentiis, Michelino e, Jung, Kyung Hae f, Manikhas, Alexey g, Abdel Azim, Hamdy h, Gupta, Kushagra i, Alexandrou, Ari j, Herraez-Baranda, Luis k, Tosti, Nadia k, Restuccia, Eleonora k |
|---|---|
| Zdroj: | In The Breast August 2022 64:151-158 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect